Published in Curr Oncol on June 01, 2012
Diagnostic applications of next generation sequencing in immunogenetics and molecular oncology. Transfus Med Hemother (2013) 0.89
A study on the effect of IL-6 gene polymorphism on the prognosis of non-small-cell lung cancer. Onco Targets Ther (2015) 0.79
Functional role of eukaryotic translation initiation factor 4 gamma 1 (EIF4G1) in NSCLC. Oncotarget (2016) 0.78
Expression of ETV6/TEL is associated with prognosis in non-small cell lung cancer. Int J Clin Exp Pathol (2015) 0.75
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature (2007) 37.09
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 32.68
K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med (2008) 27.35
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med (2010) 27.12
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med (2005) 25.93
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol (2008) 20.89
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell (2004) 19.51
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell (2007) 17.98
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol (2008) 17.30
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol (2009) 15.23
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res (2006) 13.98
Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med (2008) 13.54
Lung cancer. N Engl J Med (2008) 13.49
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene (2007) 11.85
Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science (1994) 10.45
Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer (2007) 10.27
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol (2005) 9.95
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res (2008) 9.29
Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol (1995) 9.03
BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res (2002) 8.55
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol (2004) 7.87
Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res (2009) 7.35
Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med (2006) 6.96
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol (2011) 6.69
KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res (2009) 6.10
Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res (2008) 5.18
EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol (2005) 5.07
Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest (2008) 4.95
A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res (2010) 4.51
Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol (2011) 4.37
Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. J Mol Diagn (2005) 4.21
TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. Am J Pathol (2000) 3.92
Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res (2008) 3.70
Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin Cancer Res (2006) 3.66
EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol (2009) 3.54
The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer (2005) 3.40
Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res (2010) 3.30
K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med (1990) 3.16
EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol (2009) 3.15
Rapid detection of epidermal growth factor receptor mutations in lung cancer by the SMart-Amplification Process. Clin Cancer Res (2007) 3.02
Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol (2011) 2.98
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst (2012) 2.79
Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J Clin Oncol (2010) 2.70
Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol Cancer Res (2009) 2.65
Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas. Hum Pathol (2009) 2.64
Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J Thorac Oncol (2008) 2.56
Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol (2011) 2.44
Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Mod Pathol (2008) 2.32
K-ras mutations in non-small-cell lung carcinoma: a review. Clin Lung Cancer (2006) 2.29
KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies. Lung Cancer (2009) 2.27
EGFR and KRAS mutations in lung carcinoma: molecular testing by using cytology specimens. Cancer Cytopathol (2011) 2.19
Anaplastic lymphoma kinase proteins in growth control and cancer. J Cell Physiol (2004) 2.19
Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method. Clin Cancer Res (2007) 2.15
The KRAS oncogene: past, present, and future. Biochim Biophys Acta (2005) 2.05
Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol (2007) 2.03
Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay. Clin Cancer Res (2006) 1.91
Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features. J Mol Diagn (2007) 1.77
A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer. J Thorac Oncol (2011) 1.74
Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer. J Clin Oncol (2011) 1.63
Rapid detection of epidermal growth factor receptor mutations in non-small cell lung cancer using real-time polymerase chain reaction with TaqMan-MGB probes. Cancer J (2006) 1.61
TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations. Blood (1999) 1.59
A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation. Blood (1999) 1.54
Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing. J Thorac Oncol (2011) 1.53
A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer. J Mol Diagn (2006) 1.50
Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer. J Clin Oncol (1999) 1.46
Frequency and spectrum of mutations at codons 12 and 13 of the c-K-ras gene in human tumors. Environ Health Perspect (1991) 1.44
Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression. J Thorac Oncol (2011) 1.43
Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. Oncogene (1994) 1.41
KRAS mutations predict response to EGFR inhibitors. Curr Opin Pharmacol (2008) 1.41
Are RAS mutations predictive markers of resistance to standard chemotherapy? Nat Rev Clin Oncol (2009) 1.32
Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC). Clin Lung Cancer (2011) 1.30
A comparison of ARMS and direct sequencing for EGFR mutation analysis and tyrosine kinase inhibitors treatment prediction in body fluid samples of non-small-cell lung cancer patients. J Exp Clin Cancer Res (2011) 1.27
MAGE-A family: attractive targets for cancer immunotherapy. Vaccine (2011) 1.15
Increased prevalence of EGFR-mutant lung cancer in women and in East Asian populations: analysis of estrogen-related polymorphisms. Clin Cancer Res (2008) 1.12
Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations. Cancer Chemother Pharmacol (2012) 1.09
A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma. Cancer Res (2000) 1.09
Epidermal growth factor receptor mutation in lung cancer are linked to bronchioloalveolar differentiation. Am J Surg Pathol (2006) 1.08
EGFR and KRAS mutation analysis in cytologic samples of lung adenocarcinoma enabled by laser capture microdissection. Mod Pathol (2011) 1.07
Prognostic value of specific KRAS mutations in lung adenocarcinomas. Cancer Epidemiol Biomarkers Prev (1997) 1.06
Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342. J Clin Oncol (2010) 1.06
A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer. J Thorac Oncol (2012) 1.01
HER-2/Neu alterations in non-small cell lung cancer: a comprehensive evaluation by real time reverse transcription-PCR, fluorescence in situ hybridization, and immunohistochemistry. Clin Cancer Res (2003) 1.00
Rapid and simple detection of hot spot point mutations of epidermal growth factor receptor, BRAF, and NRAS in cancers using the loop-hybrid mobility shift assay. J Mol Diagn (2006) 0.99
The status of KRAS mutations in patients with non-small cell lung cancers from mainland China. Oncol Rep (2009) 0.91
Clinical significance of BRAF gene mutations in patients with non-small cell lung cancer. Anticancer Res (2011) 0.87
A review of the role of insulin-like growth factor 2 in malignancy and its potential as a modifier of radiation sensitivity. Clin Oncol (R Coll Radiol) (2008) 0.84
Paradigm shifts in lung cancer as defined in the new IASLC/ATS/ERS lung adenocarcinoma classification. Eur Respir J (2011) 0.82
A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC). Cancer Chemother Pharmacol (2006) 0.77
Detection of epidermal growth factor receptor mutations in a few cancer cells from transbronchial cytologic specimens by reverse transcriptase-polymerase chain reaction. Mol Diagn Ther (2011) 0.76
[Primary cutaneous leiomyosarcoma: 32 cases]. Ann Dermatol Venereol (1999) 2.83
Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. Hum Mol Genet (1998) 1.88
High expression of DNA repair pathways is associated with metastasis in melanoma patients. Oncogene (2007) 1.83
[Clinical and genetic study in 22 patients with basal cell nevus syndrome]. Ann Dermatol Venereol (2006) 1.62
[Melanoma of the penis: 6 cases]. Ann Dermatol Venereol (2004) 1.42
Human tissue research: EORTC recommendations on its practical consequences. Eur J Cancer (2003) 1.40
TuBaFrost 2: Standardising tissue collection and quality control procedures for a European virtual frozen tissue bank network. Eur J Cancer (2006) 1.20
Biomarkers in melanoma. Ann Oncol (2009) 1.17
Repeatability of a lameness scoring system for finishing pigs. Vet Rec (2000) 1.15
The Janus face of dendritic cells in cancer. Oncogene (2008) 1.03
Differentiation between recurrent tumor and benign conditions after treatment of gynecologic pelvic carcinoma: value of dynamic contrast-enhanced subtraction MR imaging. Radiology (1997) 1.01
TuBaFrost 3: regulatory and ethical issues on the exchange of residual tissue for research across Europe. Eur J Cancer (2006) 1.01
EGFR and K-ras gene mutation status in squamous cell anal carcinoma: a role for concurrent radiation and EGFR inhibitors? Br J Cancer (2012) 0.98
EGFR tyrosine kinase mutation testing in the treatment of non-small-cell lung cancer. Curr Oncol (2012) 0.93
Comprehensive analysis of CDKN2A (p16INK4A/p14ARF) and CDKN2B genes in 53 melanoma index cases considered to be at heightened risk of melanoma. J Med Genet (2005) 0.92
Value of high-frequency US for preoperative assessment of skin tumors. Radiographics (1998) 0.92
TuBaFrost 1: Uniting local frozen tumour banks into a European network: an overview. Eur J Cancer (2006) 0.91
An explosive course of squamous cell penile cancer in an AIDS patient. Ann Oncol (2002) 0.88
Sporadic multiple primary melanoma cases: CDKN2A germline mutations with a founder effect. Genes Chromosomes Cancer (2001) 0.87
In vivo evolution of tumour cells after the generation of double-strand DNA breaks. Br J Cancer (2003) 0.87
[Primary anorectal melanoma. Apropos of 19 cases]. J Chir (Paris) (1997) 0.86
[Eruptive nevi associated with sorafenib treatment]. Ann Dermatol Venereol (2008) 0.86
TuBaFrost 5: multifunctional central database application for a European tumor bank. Eur J Cancer (2006) 0.85
[Delayed cerebral radionecrosis following radiation therapy of cutaneous squamous cell carcinomas of the head]. Ann Dermatol Venereol (2002) 0.84
Intratumoral oxygen tension in metastatic melanoma. Melanoma Res (1997) 0.84
Overexpression of matrix metalloproteinase 1 in dermal fibroblasts from DNA repair-deficient/cancer-prone xeroderma pigmentosum group C patients. Oncogene (2008) 0.84
Apoptosis is antagonized by large T antigens in the pathway to immortalization by polyomaviruses. Oncogene (1994) 0.84
Indium-111 octreotide scintigraphy of Merkel cell carcinomas and their metastases. Ann Oncol (2001) 0.83
Heterozygous mutations in the tumor suppressor gene PATCHED provoke basal cell carcinoma-like features in human organotypic skin cultures. Oncogene (2008) 0.82
Borderline and malignant serous tumor arising in pelvic lymph nodes: evidence of origin in benign glandular inclusions. Int J Gynecol Pathol (1995) 0.81
[Melanoma within naevus spilus: 5 cases]. Ann Dermatol Venereol (2006) 0.81
Tyrosinase-related protein 1 mRNA expression in lymph node metastases predicts overall survival in high-risk melanoma patients. Br J Cancer (2013) 0.81
Virtual microscopy in virtual tumor banking. Adv Exp Med Biol (2006) 0.80
Skin cancer incidence and survival in European children and adolescents (1978-1997). Report from the Automated Childhood Cancer Information System project. Eur J Cancer (2006) 0.80
An experimental inter-expert telepathology network using static imaging. J Clin Pathol (2001) 0.80
Dynamic contrast-enhanced subtraction versus T2-weighted spin-echo MR imaging in the follow-up of colorectal neoplasm: a prospective study of 41 patients. Radiology (1996) 0.80
TuBaFrost 6: virtual microscopy in virtual tumour banking. Eur J Cancer (2006) 0.78
TuBaFrost: European virtual tumor tissue banking. Adv Exp Med Biol (2006) 0.78
Eccrine porocarcinoma with intracerebral extension. Eur Radiol (1997) 0.77
[Significance of sentinel lymph node biopsy in Merkel cell carcinoma. Analysis of 11 cases]. Ann Dermatol Venereol (2003) 0.77
Association between germ cell tumours, large numbers of naevi, atypical naevi and melanoma. Melanoma Res (2001) 0.77
Hepatocellular carcinoma during hormonotherapy for prostatic cancer. Am J Clin Oncol (1994) 0.77
Microcystic adnexal carcinoma: report of seven cases including one with lung metastasis. Dermatology (2006) 0.77
[Cutaneous side effects of sorafenib and sunitinib]. Ann Dermatol Venereol (2008) 0.76
The potential contribution of fluorescent in situ hybridization analysis to the cytopathological diagnosis of Merkel cell carcinoma. Cytopathology (2008) 0.76
[Rare lesion of the vulva]. Arch Anat Cytol Pathol (1992) 0.76
[Cerebral magnetic resonance imaging (MRI) in the diagnosis of leptomeningeal carcinomatosis in melanoma patients]. Ann Dermatol Venereol (2000) 0.75
Laparoscopic prophylactic oophorectomy in women with inherited risk of ovarian cancer. Eur J Gynaecol Oncol (1999) 0.75
Microstaging in cutaneous melanoma. J Pathol (2001) 0.75
[Benign glandular inclusions in inguinal and abdominopelvic lymph nodes in gynecologic pathology]. Ann Pathol (1993) 0.75
Independent approach to learning. J Pract Nurs (1974) 0.75
Nucleolar organizer regions in ovarian tumors: discrimination between carcinoma and borderline tumor. Int J Gynecol Pathol (1992) 0.75
Surgical procedure in patients with ovarian cancer diagnosed at the time of prophylactic oophorectomy. Analysis of two cases, literature review and surgical implications. Eur J Obstet Gynecol Reprod Biol (2004) 0.75
TuBaFrost 4: access rules and incentives for a European tumour bank. Eur J Cancer (2006) 0.75
[Microcystic sclerosing adnexal carcinoma: 2 case reports. Diagnostic and therapeutic difficulties]. Ann Otolaryngol Chir Cervicofac (1998) 0.75
Ag NORs in evaluation of neo-adjuvant chemotherapy for gastric adenocarcinoma. Eur J Surg Oncol (1990) 0.75
Malignant melanoma and Kaposi's sarcoma: a possible additional syndrome to AIDS-related complex. AIDS (1990) 0.75
Frozen section of lymph nodes in uterine cervical carcinoma. Clin Exp Pathol (1999) 0.75
Melanoma arising de novo in childhood: experience of the Gustave-Roussy Institute. Melanoma Res (1995) 0.75
Sixteen or sixty; does it make a difference? J Pract Nurs (1975) 0.75
Surgical management for prophylactic oophorectomy in women with an inherited risk of ovarian cancer. Tumori (2001) 0.75
[Primary ano-rectal melanoma. Report of 9 cases]. Ann Pathol (1996) 0.75